semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Carcinoma Cardiovascular Complication European American patients with DNA available European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab African American cases (based on a drop in left ventricular ejection fraction [LVEF] < 50 or a drop from baseline > 20 points) and African American controls
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Eisenmenger Syndrome Congenital Heart Disease Sleep-disordered Breathing Eisenmenger Syndrome (definition: Pulmonary ≥ systemic vascular resistance with pulmonary-to-systemic shunt and cyanosis (periphery oxygen saturation < 92% at rest and/or < 87% during exercise) Stable for ≥ 3 months (no hospitalization, no change of medication, no deterioration)  Down's syndrome Iron deficiency (definition: Ferritin < 12 µg/l and/or transferring saturation < 20%) Regular phlebotomy Suspicion of risk of non-compliance
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Decompensated Heart Failure Age 18 years or older Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to inclusion Chronic heart failure will be defined as requiring treatment for a minimum of 30 days prior to current admission, NYHA Class III or IV at the time of hospitalization, and left ventricular ejection fraction less than 40% within one year or evidence of heart failure with preserved ejection fraction and evidence of diastolic dysfunction on echocardiogram Admitted with clinical decompensated heart failure based on history, physical exam, and parameters indicating extracellular volume expansion such as including JVP ≥ 8 cm of water and 1+ or greater peripheral edema Is able to be dosed with study medication within six (6) hours of first dose of IV diuretics  Baseline severe hypotension (Mean arterial pressure < 55 mm Hg) Creatinine clearance less than 20 ml/min or creatinine greater than 2.5 mg/dl Serum sodium less than 128 meq/L Serum Potassium < 3.0 meq/L Known adverse reaction to metolazone Inability to take oral medications Severe Aortic Stenosis (AVA < 0.8cm2) History of Hypertrophic obstructive cardiomyopathy Metastatic Carcinoma per history Severe COPD, FEV < 1L
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Congestive Heart Failure Age > 21 years of age Left ventricular ejection fraction ≤ 50% (at any time in the past) Symptomatic (NYHA class II-IV) heart failure (as diagnosed by clinician, radiographic images, or abnormal natriuretic peptide level) Hospital admission, Emergency Department visit, or outpatient diuretic escalation of therapy for destabilized HF at least once in the 6 months prior to enrollment  Severe renal insufficiency defined as serum creatinine > 2.5 mg/dl United Organ Network Sharing status 1B for heart transplantation (outpatient inotrope use, LV assist device) Inoperable aortic valvular heart disease Life expectancy <1 year due to causes other than HF such as advanced cancer Cardiac transplantation or revascularization indicated or expected within 6 months Severe obstructive or restrictive pulmonary disease, defined as a forced expiratory volume in 1 sec <1 L (when diagnosed as standard of care) Subject unable or unwilling to provide written informed consent Coronary revascularization (percutaneous coronary intervention or bypass surgery) within the previous 3 months
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Lung Disease Age greater than or equal to 40 years Cigarette smoking greater than or equal to 30 pack years Obstructive Spirometry First degree relative with smoking history willing to participate
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 5.0-11.0,  Asthma Siblings of a birth cohort recruited 1997-1999 Age less than 11 years Physician diagnosed asthma Active symptoms (wheeze, persistent cough, chest tightness, shortness of breath) or medication use in the 12 months prior to enrollment
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease COPD Patients must have moderate or severe COPD Patients must have at least one episode of COPD-related symptoms (eg, cough, sputum production, shortness of breath) within 2 months prior to screening Patients must not have asthma as main component of obstructive airway disease Patients must not have had a moderate or severe exacerbation of COPD within previous 1 month
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 21.0-70.0,  Healthy Volunteers (Non-smoker) Healthy Volunteers (Smoker) Chronic Obstructive Pulmonary Disease Healthy non-smokers Normal spirometry (FEV1 >90 % predicted; exhaled NO bigger than or equal to 10 ppb; flow 50 ml/s) At risk (current smokers) Normal spirometry, with or without chronic symptoms (cough, sputum production) FEV1 reversibility of <15% after inhaled beta2-agonists* Moderate COPD FEV1 greater than or equal to 30% and < 80% FEV1/FVC < 70% predicted FEV1 reversibility of <15% after inhaled beta2-agonists With or without chronic symptoms (cough, sputum production, dyspnea)  Concomitant use or pre-treatment within the last 4 weeks with oral steroids Respiratory infection within 4 weeks prior to entry into the trial Females who are pregnant or lactating History of current or past drug or alcohol abuse
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease (COPD) diagnosis of mild COPD OR healthy control subjects 80 years old able to perform all study procedures Smoking history > 10 pack years (for mild COPD) or smoking history < 10 pack years (for healthy control subjects)  allergy to atrovent history of asthma, atopy or nasal polyps Oxygen desaturation < 80 % during exercise recent history of CAD (under a year) or any significant diseases that could contribute to dyspnea or exercise limitation
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COPD Osteoporosis Osteopenia Age > 18 years Men and women COPD according to the ATS-guidelines, divided in severity according to the GOLD Written consent  Age < 18 years No written consent
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Respiratory Tract Infections General Conditions Outpatients Fulfillment of clinical diagnostic for one of the following indications Mild to moderate Community Acquired Pneumonia (CAP) Acute bacterial Exacerbation of Chronic Bronchitis (AECB) Acute Sinusitis (AS) For CAP The to be fulfilled are New onset of at least two of the following Cough  General Conditions Subjects presenting with any of the following will not be included in the study Treatment required during the study with ergot alkaloid derivatives, pimozide, astemizole, terfenadine, cisapride, simvastatin, atorvastatin and lovastatin, and the oral use of the benzodiazepines midazolam, triazolam and alprazolam History of congenital or family history of long QT syndrome (if not excluded by ECG) or known acquired QT interval prolongation Known hypersensitivity to telithromycin or to macrolide antibiotics Hospital acquired infections (hospitalization for more than 72 hours within 7 days of study entry) Pregnant or breast-feeding women. For the women of childbearing potential it is left to the investigators discretion to establish a lack of pregnancy, e.g. with contraceptive use, menstrual pattern, urinary pregnancy test Subjects with severely impaired renal function (creatinine clearance <30 ml/min) Subjects that had received anti-bacterials for more than 24 hours within 7 days prior to enrollment in the study, unless the treatment has failed Subjects receiving medications, including other anti-microbials or anti-cancer drugs, that could interfere with the evaluation
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Pulmonary Disease, Chronic Obstructive Outpatient with the diagnosis or referral diagnosis of COPD COPD must be the primary reason for this outpatient contact (for both new patients and controls)  Any co-morbidity that hampers the diagnosis and treatment of COPD in accordance with the COPD guidelines used locally (e.g. malignant disease, dementia or sequelae of apoplexy) Asthma without the presence of COPD
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  COPD Acute Exacerbation COPD patients who were admitted to our pulmonary department for an acute exacerbation were prospectively enrolled in the study  COPD patients hospitalized with specific reasons like pneumonia, pulmonary emboli, congestive heart failure, pneumothorax etc. as the cause of acute exacerbation, or patients with risk of imminent respiratory failure requiring mechanical ventilation or direct admission to the ICU were excluded
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Established clinical history of moderate to severe COPD Post bronchodilator FEV1 of < 50% of predicted normal FEV1 / FVC ratio <70% Reversibility to 400mcg albuterol of less or equal to 10 predicted at Visit 1 Free from exacerbation in the 6 weeks prior to screening Current or former smoker with a smoking history of = 10 pack-years and has a history of COPD exacerbations  Current asthma, eczema, atopic dermatitis and/or allergic rhinitis Has a known respiratory disorder other than COPD (e.g. lung cancer, sarcoidosis, tuberculosis or lung fibrosis) Has narrow-angle glaucoma, prostatic hyperplasia or obstruction of the neck of the bladder that in the opinion of the investigator should prevent the subject from entering the study Has undergone lung transplantation and/or lung volume reduction Female who is a nursing mother Requires regular (daily) long-term oxygen therapy (LTOT) Is receiving beta-blockers (except eye drops) Has a serious, uncontrolled disease likely to interfere with the study Has received any other investigational drugs within the 4 weeks prior to Visit 1 Has, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  COPD Pulmonary Hypertension Confirmed moderate to severe COPD with or without pulmonary hypertension Male and female patients Aged 18 years Written consent Adequate contraception in female patients of childbearing age Negative pregnancy test (four-weekly test repetition)  Lack of consent Pregnancy (four-weekly tests) Lactation Presumed non-cooperativeness Patients outside the stipulated age range Myocardial infarction within the last 12 months Stroke within the last 12 months Malignant diseases in anamnesis Legal incapacity Parallel participation in a clinical trial
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) diagnosis of COPD history of 15 pack-years or more of cigarette smoking evidence of irreversible obstruction (FEV1<70% of predicted value, ratio FEV1/FVC<70%, and improvement of FEV1of less than 20% after bronchodilator in previous respiratory tests done when they were stable)  history of asthma or atopy need of being hospitalized use of oral or intravenous steroid within the preceding 30 days history of multiresistant bacterial infection (not applicable if absence of multi-resistant bacterial infection has been proved by a negative expectoration culture in the previous 6 months), bronchiectasis or recent COPD exacerbation (< 6 weeks) or diabetes oxygen-dependant COPD patients or patients previously known with hypercapnia (PCO2>45 mmHg) at steady state use of high doses of Advair (more than 50/500 bid) or Symbicort (more than 12/400 bid) known cardiac arrhythmia such as atrial fibrillation, supraventricular tachycardia or paroxysmal auricular tachycardia
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Pulmonary Disease, Chronic Obstructive No change from the MIA and LEUKO trials  No change from the MIA and LEUKO trials
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) A software program using Anatomical Therapeutical Chemical (ATC) prescription codes and International Classification of Primary Care (ICPC) diagnosis codes selected potential patients with COPD. age >35 years and a diagnosis recorded as COPD or as ICPC code R95/96, or a prescription of at least three times of bronchodilators (ATC code R03a/bc) and/or prescription of at least two times of inhaled anti-inflammatory medication in the past year (ATC code R03). General practitioners (GPs) had to confirm the diagnosis of the selection. Patients were eligible to participate if they met the following Current smoking Suffering from COPD according to the GP's diagnosis In command of the Dutch language  Too ill Under control of a chest physician Serious physical or psychological comorbidity
Patient description: A 66yo female with significant smoking history and chronic cough for the past two years presents with recent, progressive shortness of breath. She is in moderate respiratory distress after walking from the waiting room to the examination room. Physical exam reveals mildly distended neck veins, a barrel-shaped chest, and moderate inspiratory and expiratory wheezes. She has smoked 1 to 2 packs per days for the past 47 years.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Pulmonary Disease, Chronic Obstructive Pulmonary Emphysema Chronic Bronchitis Subject must have a diagnosis of moderate or severe COPD Subject must have a post-bronchodilator FEV1/FVC ratio < 0.7 Subject must have a post-bronchodilator FEV1 % predicted value ≥ 30% and < 70% Subject must be between 40 and 80 years of age, of either sex, and of any race Subject must be a current or ex-smoker, with a cigarette smoking history of ≥ 10 years or > 10 pack-years  Subject has been diagnosed with asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer) Subject has been diagnosed with α1-Antitrypsin deficiency Subject has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb) Subject has active infection Subject has had a significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening Subject with clinically relevant uncontrolled medical condition not associated with COPD Subject has documented history of uncontrolled heart failure Subject has pulmonary hypertension due to left heart condition Subject has atrial fibrillation or significant congenital heart defect/disease Subject has initiated pulmonary rehabilitation within 3 months of screening